BRPI0518790A2 - formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete - Google Patents
formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tableteInfo
- Publication number
- BRPI0518790A2 BRPI0518790A2 BRPI0518790-7A BRPI0518790A BRPI0518790A2 BR PI0518790 A2 BRPI0518790 A2 BR PI0518790A2 BR PI0518790 A BRPI0518790 A BR PI0518790A BR PI0518790 A2 BRPI0518790 A2 BR PI0518790A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- capsule
- tablet
- product
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
FORMULAÇçO FARMACÊUTICA, PROCESSO PARA PREPARAR UMA FORMULAÇçO FARMACÊUTICA, PRODUTO, E, CÁPSULA OU TABLETE. A presente invenção fornece formulações de dosagem sólida de benzoxazol contendo ligantes ERB-seletivos, e processos para suas fabricações.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63246604P | 2004-12-02 | 2004-12-02 | |
PCT/US2005/043419 WO2006060542A2 (en) | 2004-12-02 | 2005-11-30 | Formulations of substituted benzoxazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518790A2 true BRPI0518790A2 (pt) | 2008-12-09 |
Family
ID=36565708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518790-7A BRPI0518790A2 (pt) | 2004-12-02 | 2005-11-30 | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060121111A1 (pt) |
EP (1) | EP1819322A2 (pt) |
JP (1) | JP2008521921A (pt) |
CN (1) | CN101111228A (pt) |
AU (1) | AU2005311833A1 (pt) |
BR (1) | BRPI0518790A2 (pt) |
CA (1) | CA2589103A1 (pt) |
WO (1) | WO2006060542A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207202A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
WO2007103869A2 (en) * | 2006-03-06 | 2007-09-13 | Wyeth | Liquid and semi-solid pharmaceutical formulations and processes |
WO2007103873A2 (en) * | 2006-03-06 | 2007-09-13 | Wyeth | Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
AR059739A1 (es) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | Formulaciones y procesos para tabletas |
US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
US20090239920A1 (en) * | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
AU2011342371B2 (en) * | 2010-12-16 | 2016-09-08 | Tuffrock Technology Pty Limited | Improved mineral based composition and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
DE60309731T2 (de) * | 2002-08-21 | 2007-06-28 | Pharmacia Corp. | Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern |
WO2004060354A1 (en) * | 2002-12-31 | 2004-07-22 | Augsburger Larry L | Methods for making pharmaceutical dosage forms containing active cushioning components |
TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
US20050232986A1 (en) * | 2003-12-17 | 2005-10-20 | David Brown | Dosage form containing promethazine and another drug |
BRPI0518789A2 (pt) * | 2004-12-02 | 2008-12-09 | Wyeth Corp | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete |
-
2005
- 2005-11-30 BR BRPI0518790-7A patent/BRPI0518790A2/pt not_active IP Right Cessation
- 2005-11-30 EP EP05852605A patent/EP1819322A2/en not_active Withdrawn
- 2005-11-30 CA CA002589103A patent/CA2589103A1/en not_active Abandoned
- 2005-11-30 US US11/290,731 patent/US20060121111A1/en not_active Abandoned
- 2005-11-30 CN CNA2005800474882A patent/CN101111228A/zh not_active Withdrawn
- 2005-11-30 JP JP2007544498A patent/JP2008521921A/ja not_active Withdrawn
- 2005-11-30 AU AU2005311833A patent/AU2005311833A1/en not_active Abandoned
- 2005-11-30 WO PCT/US2005/043419 patent/WO2006060542A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006060542A2 (en) | 2006-06-08 |
CA2589103A1 (en) | 2006-06-08 |
CN101111228A (zh) | 2008-01-23 |
WO2006060542A3 (en) | 2006-10-26 |
EP1819322A2 (en) | 2007-08-22 |
US20060121111A1 (en) | 2006-06-08 |
AU2005311833A1 (en) | 2006-06-08 |
WO2006060542A9 (en) | 2006-07-20 |
JP2008521921A (ja) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0518790A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete | |
BRPI0518789A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete | |
BRPI0518786A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete | |
CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
AR052925A1 (es) | Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
ATE482194T1 (de) | Indolonderivate, verfahren zu deren herstellung und deren anwendungen | |
BRPI0517088A (pt) | formulação de comprimido estável | |
WO2006128692A3 (en) | 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system | |
CL2007003263A1 (es) | Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e | |
CY1110115T1 (el) | Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες | |
BRPI0512756A (pt) | composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
NO20062824L (no) | 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme | |
TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
BRPI0615195A8 (pt) | preparação farmacêutica, embalagem, e, métodos para tratar doença gastrintestinal, para fabricar uma cápsula e para testar dissolução de cápsulas de balsalazida. | |
CL2008002479A1 (es) | Composicion farmaceutica que comprende: a) una o mas sustancias medicamentosas, b) un lipido, c) un co-lipido y d) un mejorador de flujo; formulacion en polvo seco; procesos de elaboracion. | |
CY1111256T1 (el) | Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους | |
WO2010127205A3 (en) | Fixed dose drug combination formulations | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
TW200718698A (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
BR0312728A (pt) | Formulação em tablete dispersìvel e processo para sua preparação | |
NO20073176L (no) | Nye medikamenter for behandling av luftveissykdommer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |